← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity

ALEC logoAlector, Inc.(ALEC)Earnings, Financials & Key Ratios

ALEC•NASDAQ
$2.57
$284M mkt cap·Price updated May 6, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryNeuroscience and Psychiatry Therapies
AboutAlector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Show more
  • Revenue$21M-79.1%
  • EBITDA-$156M-14.6%
  • Net Income-$143M-20.1%
  • EPS (Diluted)-1.39-13.0%
  • EBITDA Margin-741.3%-447.5%
  • Operating Margin-741.3%-414.1%
  • Net Margin-679.16%-473.7%
  • ROE-181.56%-99.0%
  • ROIC-170.34%-83.9%
  • Debt/Equity1.18+252.6%
Technical→

ALEC Key Insights

Alector, Inc. (ALEC) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

  • ✗Weak Piotroski F-Score: 1/9
  • ✗Negative free cash flow
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

ALEC Price & Volume

Alector, Inc. (ALEC) stock price & volume — 10-year historical chart

Loading chart...

ALEC Growth Metrics

Alector, Inc. (ALEC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-0.05%
3 Years-46%
TTM-79.07%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-20.06%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-12%

Return on Capital

10 Years-30.7%
5 Years-29.1%
3 Years-39.52%
Last Year-55.03%

ALEC Recent Earnings

Alector, Inc. (ALEC) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 9/12 qtrs (75%)
Q1 2026Latest
Feb 25, 2026
EPS
$0.34
Est $0.39
+12.8%
Revenue
$6M
Est $2M
+218.6%
Q4 2025
Nov 6, 2025
EPS
$0.34
Est $0.42
+19.0%
Revenue
$3M
Est $2M
+82.8%
Q3 2025
Aug 7, 2025
EPS
$0.30
Est $0.45
+33.3%
Revenue
$8M
Est $3M
+180.7%
Q2 2025
May 8, 2025
EPS
$0.41
Est $0.44
+6.8%
Revenue
$4M
Est $4M
-13.6%
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q1 2026LatestFeb 25, 2026
$0.34vs $0.39+12.8%
$6Mvs $2M+218.6%
Q4 2025Nov 6, 2025
$0.34vs $0.42+19.0%
$3Mvs $2M+82.8%
Q3 2025Aug 7, 2025
$0.30vs $0.45+33.3%
$8Mvs $3M+180.7%
Q2 2025May 8, 2025
$0.41vs $0.44+6.8%
$4Mvs $4M-13.6%
Based on last 12 quarters of dataView full earnings history →

ALEC Peer Comparison

Alector, Inc. (ALEC) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
PRTA logoPRTAProthena Corporation plcDirect Competitor601.85M11.18-2.47-92.84%-25.21%-73%0.05
ACAD logoACADACADIA Pharmaceuticals Inc.Direct Competitor3.68B21.489.3811.87%36.49%41.9%0.04
SAVA logoSAVACassava Sciences, Inc.Direct Competitor94.44M1.96-3.76-95.77%
AVXL logoAVXLAnavex Life Sciences Corp.Direct Competitor309.52M3.34-6.19-31.55%
INMB logoINMBINmune Bio, Inc.Direct Competitor40.41M1.52-0.72-90.97%-997.74%-172%0.01
BIIB logoBIIBBiogen Inc.Product Competitor28.15B190.6821.591.39%13.92%7.55%0.38
IONS logoIONSIonis Pharmaceuticals, Inc.Product Competitor12.7B76.85-32.2933.87%-30.87%-58.57%5.35
ARVN logoARVNArvinas, Inc.Product Competitor656.24M10.26-8.02-0.3%-30.77%-14.25%0.02

Compare ALEC vs Peers

Alector, Inc. (ALEC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs PRTA

Most directly comparable listed peer for ALEC.

Scale Benchmark

vs LLY

Larger-name benchmark to compare ALEC against a more recognizable public peer.

Peer Set

Compare Top 5

vs PRTA, ACAD, SAVA, AVXL

ALEC Income Statement

Alector, Inc. (ALEC) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25
Sales/Revenue3.73M27.68M21.22M21.1M207.09M133.62M97.06M100.56M21.05M
Revenue Growth %797.84%641.02%-23.33%-0.57%881.54%-35.48%-27.36%3.6%-79.07%
Cost of Goods Sold29.91M73.03M100.53M156.87M189.41M08.85M00
COGS % of Revenue800.83%263.87%473.76%743.53%91.46%-9.12%--
Gross Profit
-26.18M▲ 0%
-45.35M▼ 73.3%
-79.31M▼ 74.9%
-135.77M▼ 71.2%
17.68M▲ 113.0%
133.62M▲ 655.8%
88.21M▼ 34.0%
100.56M▲ 14.0%
0▼ 100.0%
Gross Margin %-700.83%-163.87%-373.76%-643.53%8.54%100%90.88%100%-
Gross Profit Growth %-97.44%-73.27%-74.87%-71.19%113.02%655.84%-33.98%13.99%-100%
Operating Expenses36.41M84.97M35.09M59.4M55.04M271.45M239.95M245.56M177.05M
OpEx % of Revenue974.94%306.99%165.39%281.56%26.58%203.16%247.22%244.19%841.3%
Selling, General & Admin6.5M11.93M33.94M59.4M55.04M61.03M56.69M59.62M53.99M
SG&A % of Revenue174.11%43.12%159.94%281.56%26.58%45.68%58.4%59.28%256.53%
Research & Development29.91M73.03M100.53M156.87M189.41M210.42M192.12M185.94M123.06M
R&D % of Revenue800.83%263.87%473.76%743.53%91.46%157.48%197.93%184.91%584.77%
Other Operating Expenses199K5.04M-99.37M-156.87M-189.41M0-8.85M00
Operating Income
-32.68M▲ 0%
-57.29M▼ 75.3%
-114.4M▼ 99.7%
-195.17M▼ 70.6%
-37.36M▲ 80.9%
-137.83M▼ 268.9%
-151.74M▼ 10.1%
-145M▲ 4.4%
-156.01M▼ 7.6%
Operating Margin %-874.94%-206.99%-539.16%-925.08%-18.04%-103.16%-156.33%-144.19%-741.3%
Operating Income Growth %-115.96%-75.31%-99.7%-70.6%80.86%-268.93%-10.09%4.44%-7.59%
EBITDA-32M-56.27M-110.63M-187.91M-29.05M-129.36M-142.89M-136.16M-156.01M
EBITDA Margin %-856.73%-203.31%-521.37%-890.65%-14.03%-96.82%-147.22%-135.4%-741.3%
EBITDA Growth %-114.31%-75.85%-96.61%-69.86%84.54%-345.38%-10.46%4.71%-14.58%
D&A (Non-Cash Add-back)680K1.02M3.77M7.26M8.31M8.47M8.85M8.84M0
EBIT-32.68M-57.29M-113.25M-195.17M-37.36M-137.83M-151.74M-145M0
Net Interest Income000000000
Interest Income000000000
Interest Expense000000000
Other Income/Expense199K5.04M9.02M4.95M1.03M7.78M26.56M26.08M13.25M
Pretax Income
-32.48M▲ 0%
-52.25M▼ 60.9%
-105.39M▼ 101.7%
-190.23M▼ 80.5%
-36.33M▲ 80.9%
-130.06M▼ 258.0%
-125.18M▲ 3.7%
-118.92M▲ 5.0%
-142.76M▼ 20.0%
Pretax Margin %-869.61%-188.78%-496.65%-901.64%-17.54%-97.33%-128.97%-118.26%-678.36%
Income Tax000003.25M5.21M128K168K
Effective Tax Rate %0%0%0%0%0%-2.5%-4.16%-0.11%-0.12%
Net Income
-32.48M▲ 0%
-52.25M▼ 60.9%
-105.39M▼ 101.7%
-190.23M▼ 80.5%
-36.33M▲ 80.9%
-133.31M▼ 267.0%
-130.39M▲ 2.2%
-119.05M▲ 8.7%
-142.93M▼ 20.1%
Net Margin %-869.61%-188.78%-496.65%-901.64%-17.54%-99.77%-134.34%-118.39%-679.16%
Net Income Growth %-114.96%-60.86%-101.7%-80.51%80.9%-266.95%2.19%8.7%-20.06%
Net Income (Continuing)-32.48M-52.25M-105.39M-190.23M-36.33M-133.31M-130.39M-119.05M-142.93M
Discontinued Operations000000000
Minority Interest000000000
EPS (Diluted)
-0.63▲ 0%
-0.76▼ 20.6%
-1.62▼ 113.2%
-2.45▼ 51.2%
-0.45▲ 81.6%
-1.62▼ 260.0%
-1.56▲ 3.7%
-1.23▲ 21.2%
-1.39▼ 13.0%
EPS Growth %64.61%-20.63%-113.16%-51.23%81.63%-260%3.7%21.15%-13.01%
EPS (Basic)-0.63-0.76-1.62-2.45-0.45-1.62-1.56-1.23-1.39
Diluted Shares Outstanding51.22M68.37M61.73M77.76M80.42M82.47M83.73M96.59M103M
Basic Shares Outstanding51.22M68.37M61.73M77.76M80.42M82.47M83.73M96.59M103M
Dividend Payout Ratio---------

ALEC Balance Sheet

Alector, Inc. (ALEC) balance sheet — assets, liabilities & shareholders' equity

Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25
Total Current Assets232.97M293.18M357.44M421.51M749.71M726.43M565.81M424.82M266.45M
Cash & Short-Term Investments32.45M290.41M353.07M413.31M735.25M712.85M548.86M413.4M256.02M
Cash Only32.45M65.47M89.64M49.97M329.15M154.32M74.56M33.02M65.8M
Short-Term Investments0224.94M263.43M363.34M406.1M558.53M474.31M380.38M190.22M
Accounts Receivable200.24M0007.39M2.59M000
Days Sales Outstanding19.57K---13.037.07---
Inventory000000000
Days Inventory Outstanding---------
Other Current Assets02.77M000016.95M11.42M10.43M
Total Non-Current Assets3.09M15.18M64.48M66.74M64.94M61.21M56.02M43.49M26.79M
Property, Plant & Equipment2.83M10.94M62.33M62.65M57.9M53.33M47.06M37.1M24.55M
Fixed Asset Turnover1.32x2.53x0.34x0.34x3.58x2.51x2.06x2.71x0.86x
Goodwill000000000
Intangible Assets000000000
Long-Term Investments01.47M0000000
Other Non-Current Assets252K2.77M2.15M4.09M7.05M7.88M8.96M6.39M2.23M
Total Assets
236.06M▲ 0%
308.36M▲ 30.6%
421.91M▲ 36.8%
488.25M▲ 15.7%
814.66M▲ 66.9%
787.65M▼ 3.3%
621.83M▼ 21.1%
468.3M▼ 24.7%
293.24M▼ 37.4%
Asset Turnover0.02x0.09x0.05x0.04x0.25x0.17x0.16x0.21x0.07x
Asset Growth %336.25%30.63%36.83%15.72%66.85%-3.32%-21.05%-24.69%-37.38%
Total Current Liabilities27.4M13.04M61.97M68.09M139.56M93.81M177.95M125.06M69.5M
Accounts Payable1.14M126K278K3M4.75M4.19M3.77M2.21M1.69M
Days Payables Outstanding13.910.631.016.999.15-155.73--
Short-Term Debt000000009.42M
Deferred Revenue (Current)18.98M34.91M30.16M23.89M90.8M48.23M82.97M23.66M6.68M
Other Current Liabilities5.6M9.56M5.73M7.29M11.66M12.76M54.74M54.55M51.71M
Current Ratio8.50x22.48x5.77x6.19x5.37x7.74x3.18x3.40x3.83x
Quick Ratio8.50x22.48x5.77x6.19x5.37x7.74x3.18x3.40x3.83x
Cash Conversion Cycle---------
Total Non-Current Liabilities260.69M392.71M165.2M152.63M374.38M479.4M309.72M216.44M193.09M
Long-Term Debt00000009.39M26.81M
Capital Lease Obligations0041.47M43.74M39.81M35.27M30.46M24.38M0
Deferred Tax Liabilities000000000
Other Non-Current Liabilities77.54M7.57M493K472K158K759K68.42M10.51M166.27M
Total Liabilities288.09M405.76M227.17M220.72M513.93M573.21M487.67M341.5M262.59M
Total Debt0048.04M51.26M47.6M43.33M38.92M42.52M36.23M
Net Debt-32.45M-65.47M-41.6M1.29M-281.55M-111M-35.64M9.5M-29.57M
Debt / Equity--0.25x0.19x0.16x0.20x0.29x0.34x1.18x
Debt / EBITDA---------
Net Debt / EBITDA---------
Interest Coverage---------
Total Equity
-52.03M▲ 0%
-97.4M▼ 87.2%
194.74M▲ 299.9%
267.53M▲ 37.4%
300.72M▲ 12.4%
214.44M▼ 28.7%
134.16M▼ 37.4%
126.8M▼ 5.5%
30.65M▼ 75.8%
Equity Growth %-108.91%-87.19%299.95%37.38%12.41%-28.69%-37.44%-5.48%-75.83%
Book Value per Share-1.02-1.423.153.443.742.601.601.310.30
Total Shareholders' Equity-52.03M-97.4M194.74M267.53M300.72M214.44M134.16M126.8M30.65M
Common Stock1K1K7K8K8K8K8K9K11K
Retained Earnings-62.19M-114.44M-219.82M-410.05M-446.38M-579.69M-710.08M-829.13M-972.06M
Treasury Stock0193.44M0000000
Accumulated OCI-980K-42K142K614K-943K-4.58M184K261K166K
Minority Interest000000000

ALEC Cash Flow Statement

Alector, Inc. (ALEC) cash flow — operating, investing & free cash flow history

Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25
Cash from Operations-17.77M127.46M-99.31M-166.73M298.55M-20.33M-184.16M-229.91M-184.03M
Operating CF Margin %-475.8%460.54%-468.01%-790.28%144.17%-15.21%-189.74%-228.63%-874.46%
Operating CF Growth %-36.77%817.26%-177.91%-67.9%279.06%-106.81%-805.91%-24.84%19.95%
Net Income-32.48M-52.25M-105.39M-190.23M-36.33M-133.31M-130.39M-119.05M-142.93M
Depreciation & Amortization680K1.02M5.57M7.26M8.31M8.47M8.85M8.84M-861K
Stock-Based Compensation5.35M6.92M16.28M30.52M40.78M46.15M42.8M39.46M26.66M
Deferred Taxes000000000
Other Non-Cash Items6.78M-2.59M-3.5M929K2.1M-1.16M-15.27M-12.17M-66.9M
Working Capital Changes8.68M174.36M-12.27M-15.22M283.68M59.53M-90.15M-146.99M0
Change in Receivables-20K238K00-7.39M4.8M2.59M00
Change in Inventory6.58M2.45M0000000
Change in Payables-41K-809K152K2.41M1.92M-572K-377K-1.44M-524K
Cash from Investing-801K-224.12M-48.87M-105.05M-49.66M-159.01M101.92M107.13M196.6M
Capital Expenditures-801K-1.88M-15.27M-5.03M-3.25M-4.12M-2.38M-1.25M-41K
CapEx % of Revenue21.45%6.81%71.94%23.85%1.57%3.08%2.45%1.25%0.19%
Acquisitions000100.02M00000
Investments---------
Other Investing0-222.24M0-100.02M00000
Cash from Financing-15K131.15M172.35M232.11M30.3M4.51M2.55M81.54M20.21M
Debt Issued (Net)00000009.39M0
Equity Issued (Net)001000K1000K01000K1000K1000K0
Dividends Paid000000000
Share Repurchases-15K-1.9M0000000
Other Financing-15K131.15M07.51M30.3M001.04M20.21M
Net Change in Cash
-18.59M▲ 0%
34.49M▲ 285.6%
24.17M▼ 29.9%
-39.67M▼ 264.1%
279.18M▲ 803.7%
-174.83M▼ 162.6%
-79.69M▲ 54.4%
-41.23M▲ 48.3%
32.78M▲ 179.5%
Free Cash Flow
-18.57M▲ 0%
125.58M▲ 776.2%
-114.57M▼ 191.2%
-171.77M▼ 49.9%
295.3M▲ 271.9%
-24.45M▼ 108.3%
-186.54M▼ 663.1%
-231.16M▼ 23.9%
-184.07M▲ 20.4%
FCF Margin %-497.24%453.73%-539.95%-814.13%142.6%-18.3%-192.19%-229.88%-874.66%
FCF Growth %-21.84%776.18%-191.24%-49.92%271.92%-108.28%-663.08%-23.92%20.37%
FCF per Share-0.361.84-1.86-2.213.67-0.30-2.23-2.39-1.79
FCF Conversion (FCF/Net Income)0.55x-2.44x0.94x0.88x-8.22x0.15x1.41x1.93x1.29x
Interest Paid000000000
Taxes Paid000000000

ALEC Key Ratios

Alector, Inc. (ALEC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric2016201720182019202020212022202320242025
Return on Equity (ROE)----216.52%-82.3%-12.79%-51.75%-74.81%-91.24%-181.56%
Return on Invested Capital (ROIC)-----69.38%-19.46%-168.61%-112.7%-92.62%-170.34%
Gross Margin-3187.02%-700.83%-163.87%-373.76%-643.53%8.54%100%90.88%100%-
Net Margin-3632.21%-869.61%-188.78%-496.65%-901.64%-17.54%-99.77%-134.34%-118.39%-679.16%
Debt / Equity---0.25x0.19x0.16x0.20x0.29x0.34x1.18x
FCF Conversion0.86x0.55x-2.44x0.94x0.88x-8.22x0.15x1.41x1.93x1.29x
Revenue Growth-797.84%641.02%-23.33%-0.57%881.54%-35.48%-27.36%3.6%-79.07%

ALEC SEC Filings & Documents

Alector, Inc. (ALEC) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Feb 25, 2026·SEC

Material company update

Dec 12, 2025·SEC

Material company update

Nov 6, 2025·SEC

10-K Annual Reports

4
FY 2026

Feb 25, 2026·SEC

FY 2025

Feb 26, 2025·SEC

FY 2024

Feb 27, 2024·SEC

10-Q Quarterly Reports

6
FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 7, 2025·SEC

FY 2025

May 8, 2025·SEC

ALEC Frequently Asked Questions

Alector, Inc. (ALEC) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Alector, Inc. (ALEC) reported $21.0M in revenue for fiscal year 2025. This represents a 4959% increase from $0.4M in 2016.

Alector, Inc. (ALEC) saw revenue decline by 79.1% over the past year.

Alector, Inc. (ALEC) reported a net loss of $142.9M for fiscal year 2025.

Dividend & Returns

Alector, Inc. (ALEC) has a return on equity (ROE) of -181.6%. Negative ROE indicates the company is unprofitable.

Alector, Inc. (ALEC) had negative free cash flow of $184.1M in fiscal year 2025, likely due to heavy capital investments.

Explore More ALEC

Alector, Inc. (ALEC) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.